Sobisis

Quick links to important sections

Sobisis

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sobisis

Sobisis is a brand name for a medication whose active pharmaceutical ingredient is sodium bicarbonate (NaHCO3). Sodium bicarbonate is an established medical agent categorized as an alkalinizing agent and an antacid.

Mechanism of Action and Uses

The primary function of the active ingredient is to act as a buffer by providing bicarbonate ions to the body. This helps neutralize excess acid and plays a role in correcting the body's acid-base balance.

Sobisis is primarily prescribed for the management of metabolic acidosis, a condition where the body accumulates too much acid. This imbalance can occur due to various underlying issues, including chronic kidney disease (CKD), severe dehydration, or diabetic ketoacidosis. By raising the blood pH, the medication works to reverse the clinical signs of acidosis.

Additionally, in its oral form, the active ingredient is commonly used to provide temporary relief from symptoms of hyperacidity, such as heartburn and acid indigestion, by neutralizing stomach acid.

Regulatory References

  1. sodium bicarbonate
  2. metabolic acidosis

What side effects are possible with Sobisis?

Possible side effects and safety information

The safety profile of Sobisis, which contains sodium bicarbonate, is primarily defined by its effects on fluid balance and systemic acid-base regulation, as documented in regulatory sources.

Officially Documented Adverse Reactions

Adverse effects are categorized by the systems they affect. Common effects are often gastrointestinal, while more serious outcomes are linked to metabolic disturbances.

System-Organ Class Common Adverse Reactions
Gastrointestinal Disorders Belching, gassiness (flatulence), abdominal distention.
Metabolism and Nutrition Fluid retention (edema), hypernatremia (high sodium levels).

Serious adverse reactions, which are not known for their frequency, are highlighted in official labeling. These include the development of metabolic alkalosis—a state of excessive blood alkalinity—especially with high doses or in patients with impaired kidney function. Other serious, rare outcomes include pulmonary edema (fluid in the lungs) due to fluid overload, and spontaneous stomach rupture associated with rapid oral ingestion.

Safety Considerations for Specific Populations

Regulatory documents specify caution for several populations. Older adults and individuals with renal impairment carry an increased risk of sodium retention and metabolic alkalosis. In neonates and pediatric patients, rapid administration of hypertonic solutions is linked to a documented risk of intracranial hemorrhage.

Time and Dose-Related Safety Patterns

Official prescribing information notes that chronic or prolonged use is associated with a greater risk of developing alkalosis and, with concomitant use of calcium, milk-alkali syndrome. Furthermore, the rate of administration is a safety factor, as rapid delivery can increase the risk of hypernatremia.

Overdose and Emergency Response

Sobisis overdose is defined in official regulatory documents by its primary physiological consequence: Metabolic Alkalosis. This imbalance results from excessive systemic bicarbonate and is characterized by laboratory findings such as Hypernatremia, Hypokalemia, and Hyperosmolarity. Overdose may present clinically with signs including Hyperirritability, Tetany (severe muscle spasms), and Severe Headache.


Regulatory information documents that severe or life-threatening outcomes can occur, including Gastric Rupture with oral use, Cerebral Oedema, and progression to Coma. Emergency medical help must be sought immediately if an overdose is suspected. Government guidance explicitly requires calling emergency services when critical symptoms manifest, such as Collapse, Seizure, or Trouble Breathing.


The official prescribing information notes that no specific antidote is known for this overdose. Management, therefore, is focused on supportive care, including the administration of intravenous 0.9% Sodium Chloride to correct fluid imbalances and Potassium Chloride or Calcium Gluconate to manage documented electrolyte abnormalities. Furthermore, an increased risk of severe complications, including Intraventricular Hemorrhage, is specifically noted for neonates and children under 2 with rapid intravenous administration.

Therapeutic Uses of Sobisis

Quick Facts: Sobisis Therapeutic Domains

  • May offer relief from symptoms of acid indigestion.
  • Used for the management of heartburn and sour stomach.
  • May be prescribed to help correct metabolic acidosis.
  • Used to help make the urine less acidic in certain clinical situations.

Sobisis, which contains the active ingredient sodium bicarbonate, is utilized in the healthcare setting for several therapeutic purposes focused on managing the body's acid-base balance. The primary use for many patients is the temporary relief of discomfort associated with common digestive issues such as acid indigestion, heartburn, and sour stomach.

In addition to its role as an antacid, the medication may be administered to help address metabolic acidosis, a condition characterized by high levels of acid in the blood. This condition can occur secondary to other clinical issues, including severe renal disease or certain drug toxicities. By helping to increase the level of bicarbonate in the blood, the medication may restore equilibrium. It may also be used to alkalinize (make less acidic) the urine in certain clinical scenarios, which assists in the management of specific conditions. Use of this medication should always align with a healthcare professional's recommendation for the specific condition being managed.

Regulatory References

  1. NIH StatPearls guidance

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility information for Sobisis (Sodium Bicarbonate), as mandated by government regulatory agencies.

Eligibility Status Patient Populations
Contraindicated (Must NOT use) Patients with metabolic or respiratory alkalosis; those with hypocalcemia (low calcium levels); or individuals losing chlorides (e.g., from vomiting or continuous GI suction). The oral form is also contraindicated following the acute ingestion of strong mineral acids.
Use with Extreme Caution (Conditional) Patients with congestive heart failure, severe renal insufficiency (kidney disease), hypertension (high blood pressure), or other conditions involving edema (swelling) and sodium retention. This includes individuals on a salt-restricted diet.

Age and Life Stage Rules:

  • Children (Pediatric Use): Use in children under 12 years of age is generally not recommended without a doctor's consultation. For infants, rapid administration of concentrated solutions is restricted to limit the risk of neurological complications.
  • Pregnancy and Lactation: Use in pregnancy is advised only when clearly needed (FDA Pregnancy Category C). It is unknown if the medication is excreted in breast milk; caution and medical advice are necessary for breastfeeding mothers.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for the active ingredient in Sobisis is defined by pharmacokinetic and pharmacodynamic interactions.

A Contraindicated Combination status is documented for eltrombopag due to significant inhibition of its gastrointestinal absorption. To mitigate this effect, official labeling requires eltrombopag and Sobisis to be administered with a mandatory separation of at least four hours.

The medication's ability to raise gastric pH also affects the exposure of other oral drugs. This increase in stomach alkalinity reduces the level or effect of medicines that require an acidic environment for absorption, such as certain antifungal agents (ketoconazole) and selected antiviral drugs (atazanavir). To manage this risk, a general rule of separating administration of all other oral medicines by one to two hours is specified.

Furthermore, Sobisis affects drug elimination by alkalinizing the urine. This action increases the renal clearance of acidic drugs like salicylates and lithium, potentially decreasing their therapeutic effect. Conversely, the clearance of certain basic drugs, such as quinidine and amphetamines, is reduced, which may prolong their exposure. Pharmacodynamic interactions are also documented: co-administration with potassium-depleting diuretics may lead to hypochloraemic alkalosis, and caution is noted with corticosteroids due to the enhanced risk of fluid retention from the additive sodium load. Finally, regulatory documents state the product should not be taken with large amounts of milk or milk products due to the risk of Milk-Alkali Syndrome.

Mechanism of Action

Bicarbonate Buffering and Acid Neutralization

The core mechanism involves the introduction of bicarbonate ions ( HCO3^-), the primary molecular target, into the blood. HCO3^- acts as a direct buffer by chemically neutralizing excess hydrogen ions ( H^+), a process that immediately acts to influence the acid-base balance pathway. This direct buffering action increases the pH of the plasma.

Systemic pH Modulation and Reserve Replenishment

By supplying and maintaining the HCO3^- reserve, the medication exerts a modulating effect on systemic acid-base homeostasis. This mechanism is characterized by a rise in the blood's pH (alkalization), which modulates the pH of extracellular fluids.

Modifying the Urinary Excretion Pathway

Excess bicarbonate that is not consumed systemically is filtered by the kidneys, entering the renal excretion pathway. This process leads to an increase in the concentration of base in the renal tubules, resulting in urinary alkalization. This physiological change modifies pH-dependent excretion dynamics.

Dosage and Administration Information

Instruction Map: How to Use Sobisis — Official Administration Guidelines

Sobisis, a brand name for sodium bicarbonate, is used according to highly specific administration protocols, which dictate route, dose, and frequency based on the treatment context.


Administration Scope

Category Official Instructions
Route of Administration The medicine is approved for Oral administration (e.g., tablets) and Intravenous (IV) injection/infusion for systemic use.
Dosing Schedule Antacid: The typical adult dose is 650 mg to 2600 mg every four hours. Systemic IV: Dosing is calculated individually, with typical correction ranges of 2 to 5 mEq/kg infused over 4–8 hours.
Timing in relation to meals Oral forms should not be taken when the stomach is overly full and require a 1- to 2-hour interval from other oral medications.
Preparation requirements Oral tablets may be swallowed whole or dissolved completely in water. For neonatal IV use, the 8.4% solution must be diluted 1:1 with 5% dextrose.
Age-group administration rules The maximum daily antacid dose for adults 60 years and older (max 7.8 g) is lower than for younger adults. Infants/Neonates are restricted to an IV administration rate of no more than 8 mEq/kg per day.
Missed-dose rules (Explicit instructions for missed doses are not consistently detailed in official summaries for this compound and are therefore excluded.)
Special procedural conditions Systemic IV administration requires continuous monitoring of arterial pH and electrolytes. Extravascular infiltration must be avoided due to the hypertonic nature of the solution.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Dual: Oral (Outpatient) and Intravenous (Controlled Setting).
Frequency pattern As-needed (Oral Antacid) and Monitored/Titrated (Systemic IV).
Regulatory basis Protocols are derived from official prescribing information.
Use-context constraints Short-term (Oral, max two weeks) and Controlled/Monitored (IV, with continuous lab oversight).

Resulting Procedural Structure

Official step sequence:

  • Oral use is limited to short-term, as-needed dosing every four hours, with a lower daily maximum for older adults.
  • Systemic IV administration necessitates prior dilution for infants and constant monitoring of blood pH and electrolytes to guide repeat dosing.
  • The administration must adhere to preparation instructions, such as dissolving oral forms and avoiding a full stomach, to ensure procedural integrity.

Connection to the Overall Use Protocol

The official usage protocol defines a temporary, intermittent oral use distinct from a highly controlled intravenous use that requires strict, continuous clinical oversight. These distinct profiles govern everything from the physical preparation of the medicine to the frequency and maximum dose allowed for specific populations.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the evidence related to this treatment option (Sodium Bicarbonate).


Summary of Core Evidence

This section summarizes the evidence reporting on studies that evaluated whether the treatment was related to changes in symptoms and examined potential long-term changes in inflammation. The body of evidence consists primarily of Phase 3 randomized controlled trials (RCTs) and long-term observational extension studies. For its primary use, the compound is a well-established alkalinizing agent used to manage metabolic acidosis, particularly in the context of Chronic Kidney Disease (CKD).


Efficacy and Symptom Changes

Phase 3 trials reported findings suggesting that the drug may be associated with changes in tender and swollen joint counts, disease activity scores, and examined the time course of changes in joint pain in specific inflammatory conditions. The primary studies included patients with active disease who had an inadequate response to prior therapy. Studies of comparative efficacy also explored whether the drug had differing outcomes when compared to other treatments. The studies that reported this comparison did so over a 12-week period.


Safety and Tolerability Profile

Studies reported on the frequency of adverse events in most adults who participated in the trials. The most frequently reported adverse events included mild infections and injection site reactions. The safety profile was evaluated across all included clinical trials. Long-term studies evaluated whether the initial reported changes persisted over five years. Studies of the safety profile did not include people with severe liver impairment.


Effect on Disease Progression

Long-term studies also examined whether the drug was associated with changes in the progression of joint destruction, as measured by radiographic scores over a two-year period. Furthermore, large observational studies in CKD patients examined associations between the drug's use and outcomes such as the rate of kidney function decline and cardiovascular events. These studies mainly included patients who had not previously received a biologic treatment.

Key Studies & References

  1. Efficacy of Sodium Bicarbonate in Slowing Progression of CKD and Improving Nutritional Status

Frequently Asked Questions (FAQ)

Common questions about Sobisis (FAQ)

Q: How quickly does Sobisis usually start working?

A: The official product information indicates that the medication has a rapid onset of action when administered intravenously for systemic use. For the oral forms, which are used as an antacid, the relief is generally intended to be temporary, but official labels do not specify an exact time frame for when the effect begins.

Q: How long does the effect of one dose of Sobisis typically last?

A: While regulatory documents do not state a precise duration of effect, the recommended oral antacid dosing is generally administered every four hours. This frequency is related to the anticipated duration of symptomatic relief provided by a single dose.

Q: What kind of studies have been done on Sobisis?

A: The evidence base for the active ingredient includes Phase 3 randomized controlled trials (RCTs) and long-term observational studies. These studies have primarily examined its use in conditions like metabolic acidosis often associated with Chronic Kidney Disease (CKD).

Q: Is there a maximum amount of time Sobisis is usually recommended for use?

A: For its use as an over-the-counter antacid, official consumer labeling advises against using the maximum dosage for more than two weeks. Prolonged use beyond this period is generally managed under the direction of a healthcare provider.

Q: Does Sobisis affect how other medications are absorbed?

A: Yes, regulatory documents indicate that this medication can affect the absorption of other drugs. Because it raises the stomach's pH (makes it less acidic), it may reduce the level or effect of many other oral medicines that require an acidic environment to be properly absorbed into the body.

Q: Can Sobisis be used if someone is on a low-salt diet?

A: Official labeling places patients on a salt-restricted diet under the category of Use with Extreme Caution. This is due to the drug's high sodium content, which could lead to fluid retention or other related complications.

Q: Can Sobisis be taken with a meal, or is an empty stomach better?

A: Regulatory instructions state that the oral form should not be taken when the stomach is overly full. Additionally, official instructions specify separating the administration from other oral drugs by a one- to two-hour interval.

Q: What is the difference between Sobisis and other common antacids?

A: Sobisis's active ingredient is categorized by regulatory bodies as both an antacid and a systemic alkalinizing agent. This means it not only neutralizes acid in the stomach but also influences the overall acid-base balance in the blood, which may distinguish it from other antacids that only work locally in the stomach.

Q: How does Sobisis differ from potassium citrate?

A: Sobisis's active ingredient is sodium bicarbonate, which introduces sodium ions. Potassium citrate is a different compound used as an alkalinizing agent that provides potassium ions. The different chemical composition means they can be used for different medical purposes, such as specifically modifying urine pH.

Q: Does Sobisis affect my body's natural balance?

A: Yes. The medication’s primary function is to introduce bicarbonate ions ( HCO3^-), which directly influence the acid-base balance pathway of the body. This is how the medication helps modulate systemic pH in conditions where the body's natural balance is disturbed.

Q: Are there any common foods or drinks that interact with Sobisis?

A: Official documents caution that the product should not be taken with large amounts of milk or milk products due to the risk of Milk-Alkali Syndrome. Furthermore, the product information notes that use requires caution with foods or diets high in sodium.

Q: Is Sobisis something I can take every day for a long period?

A: Official prescribing information notes that chronic or prolonged use of the active ingredient is associated with an increased risk of developing alkalosis (excessive blood alkalinity) and milk-alkali syndrome.

Q: What happens if I miss taking a scheduled dose of Sobisis?

A: Regulatory documents describe taking a missed dose as soon as it is remembered, unless it is almost time for the next dose. Consumer information indicates that a double dose should not be taken to make up for a missed one.

Q: Can Sobisis change the color of my urine?

A: Because the active ingredient increases the concentration of base in the kidneys, it leads to urinary alkalization. This physiological change affects the excretion of various substances, which may result in a noticeable change in the characteristics of the urine.

Q: What official health agencies have approved Sobisis?

A: The official protocols and prescribing information for this medication are derived from major governmental regulatory bodies. These include agencies such as the FDA / DailyMed in the United States and the EMA / MHRA in the United Kingdom and Europe.

Q: Are there common signs that Sobisis is not agreeing with my body?

A: One potential serious effect noted in regulatory documents is the development of metabolic alkalosis, a state of excessive blood alkalinity. Signs that may be associated with this condition include muscular twitchings, irritability, and tetany.

Q: Is Sobisis available over the counter in some places?

A: Official information confirms that oral forms of the active ingredient are available as an Over-The-Counter (OTC) drug for short-term antacid use. However, the injectable intravenous solution is classified as a prescription-only medication.

Q: What are the main ingredients in Sobisis?

A: The active pharmaceutical ingredient (API) in Sobisis is sodium bicarbonate ( NaHCO3). The drug product also contains various inactive ingredients, which may differ depending on the specific formulation (e.g., tablet vs. solution).

Q: Is Sobisis known to cause headaches or dizziness?

A: Official safety documents do not list headaches as a common side effect. However, dizziness is noted in some general safety information as a possible, though not frequently reported, adverse reaction.

Q: Does Sobisis contain any sugar or gluten?

A: Regulatory labels for the active ingredient often list standard inactive ingredients like cellulose or oils. Official labels for the active ingredient often do not include explicit claims regarding the presence or absence of sugar or gluten, as this can vary by the specific product manufacturer and formulation.

Q: Are there any known severe or rare side effects associated with Sobisis?

A: Yes, official labeling highlights several severe or rare adverse reactions. These include the development of metabolic alkalosis (excessive blood alkalinity), pulmonary edema (fluid in the lungs), and, rarely, spontaneous stomach rupture associated with rapid oral ingestion.

Q: Is there a generic version of Sobisis available?

A: Yes. Since Sobisis is a brand name for the active ingredient sodium bicarbonate, this compound is widely available as a lower-cost generic product through various manufacturers.

Q: How is Sobisis eliminated from the body?

A: Excess bicarbonate that is not used by the body to neutralize acid is filtered by the kidneys and enters the renal excretion pathway. The medication's active compound is primarily eliminated from the body via the urine.

Q: Does Sobisis affect breathing or cause shortness of breath?

A: Yes, official labeling notes that a rare but serious outcome linked to fluid overload is pulmonary edema (fluid in the lungs). This condition can be associated with difficulty breathing or shortness of breath.

Q: Is there a possibility of becoming dependent on Sobisis?

A: Regulatory labeling for the active ingredient explicitly states that there is no potential for drug abuse or drug dependence associated with its use.

Q: What is the purpose of Sobisis if the body can regulate its own pH?

A: The medication is typically prescribed for conditions like metabolic acidosis, where the body's natural regulatory systems are overwhelmed or malfunctioning. In such cases, the pH balance has shifted due to an accumulation of too much acid, requiring external buffering support to restore equilibrium.

How should Sobisis be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict requirements for storing, handling, and disposing of Sobisis (Sodium Bicarbonate) tablets to maintain product quality and safety.

Storage and Handling

  • Temperature: Store the tablets at a temperature not exceeding 30 C in a cool and dry place.
  • Protection: The medicine must be protected from light and moisture to prevent degradation.
  • Child Safety: It is strictly required to keep the medicine out of the reach and sight of children at all times.

Disposal Instructions

  • General Rule: Unused or expired Sobisis must be disposed of properly according to local, regional, and national regulations.
  • Prohibitions: Do not flush the tablets down a toilet or throw them into a drain or sewer system.
  • Environmental Safety: Prevent release to the environment and retain and dispose of contaminated wash water appropriately.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sobisis found in:

A-Z Index: